Circio Holding ASA (LTS:0RIS) Research & Development: kr11.59 Mil (TTM As of Dec. 2025)


LTS:0RIS Circio Holding ASA LTS:0RIS
25 GF Score
Price kr7.26
! 3 Warning Signs
View Full Analysis

What is Circio Holding ASA Research & Development?

Circio Holding ASA LTS:0RIS 25 Research & Development is kr11.59 Mil as of Dec. 2025. GuruFocus rates LTS:0RIS with a GF Score™ of 25/100. The stock has 3 warning signs investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. Circio Holding ASA's Research & Development for the six months ended in Dec. 2025 was kr5.65 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Dec. 2025 was kr11.59 Mil.

Circio Holding ASA  (LTS:0RIS) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Circio Holding ASA Research & Development Related Terms

Circio Holding ASA Research & Development Historical Data

* Premium members only.

The historical data trend for Circio Holding ASA's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Circio Holding ASA Research & Development Chart

Circio Holding ASA Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Research & Development
Get a 7-Day Free Trial Premium Member Only Premium Member Only 37.44 47.23 49.89 11.69 11.59

Circio Holding ASA Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 7.46 7.46 4.23 5.93 5.65
LTS:0RIS
25GF Score
Circio Holding ASA LTS:0RIS
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Circio Holding ASA Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was kr11.59 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of kr11.59 Mil mean?
Circio Holding ASA (LTS:0RIS) has a Research & Development of kr11.59 Mil as of Dec. 2025. Research and development expense is the total cost for research and development activities. View historical data on Circio Holding ASA and its competitors.
Is Circio Holding ASA's Research & Development too high?
Circio Holding ASA's current Research & Development is kr11.59 Mil. Overall, Circio Holding ASA has a GF Score™ of 25/100, reflecting its overall financial health beyond just this single metric.
How does Circio Holding ASA's Research & Development compare to VRTX and REGN?
Circio Holding ASA's Research & Development of kr11.59 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Biotechnology company?
A good Research & Development depends on the Biotechnology industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on Circio Holding ASA and its competitors. Circio Holding ASA's current Research & Development is kr11.59 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Circio Holding ASA stock overvalued right now?
Circio Holding ASA (LTS:0RIS) has a current Research & Development of kr11.59 Mil. The current Research & Development is kr11.59 Mil. Circio Holding ASA's overall GF Score™ is 25/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For Circio Holding ASA (LTS:0RIS), the current Research & Development is kr11.59 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Circio Holding ASA Business Description

Other Exchanges CRNA:NorwayTA50:Germany
Address c/o Mesh Community AS, Tordenskiolds Gate 2, Oslo, NOR, 0160
Circio Holding ASA is a biotechnology company developing circular RNA expression technology for gene and cell therapy applications. It has developed a circular RNA (circRNA) vector expression platform known as circVec, which is based on modular genetic constructs designed for circRNA production within target cells. The platform is being developed for applications including genetic medicine, cell therapy, and chronic disease treatment. The company's activities also include the development of RNA, DNA, and viral therapeutic technologies related to gene expression and protein production.
25GF Score

Get the complete analysis for LTS:0RIS

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr7.26
Price